Inhibikase Therapeutics Initiates Phase 3 IMPROVE-PAH Trial for Novel Pulmonary Arterial Hypertension Treatment
Key Insights
Inhibikase Therapeutics has enrolled the first patient in its pivotal Phase 3 IMPROVE-PAH (search) study evaluating IKT-001 (search), a novel oral prodrug of imatinib designed to reduce gastrointestinal side effects in pulmonary arterial hypertension (search) patients.
The global two-part adaptive trial will assess approximately 486 patients across 180 sites worldwide, with Part A focusing on pulmonary vascular resistance changes and Part B measuring 6-minute walk distance improvements.
The study incorporates a 12-week dose-titration phase and adaptive design features that could accelerate the timeline to potential NDA filing for this orphan indication affecting approximately 50,000 Americans.
Inhibikase Therapeutics has achieved a significant milestone by enrolling the first patient in its pivotal Phase 3 IMPROVE-PAH (search) study, marking the beginning of a global trial evaluating IKT-001 (search) for the treatment of pulmonary arterial hypertension (search) (PAH). The clinical-stage pharmaceutical company announced this development as part of its strategy to accelerate the timeline to potential New Drug Application (NDA) filing for this orphan indication.
Novel Prodrug Design Addresses Treatment Limitations
IKT-001 (search) represents a novel oral prodrug of imatinib mesylate specifically designed to reduce gastrointestinal side effects commonly observed with imatinib. Mark Iwicki, Chief Executive Officer of Inhibikase, described the enrollment as "a major milestone for Inhibikase, and the result of many months of work to optimize the IKT-001 study plan to permit a single pivotal global study and significantly accelerate the timeline to potential NDA filing."
The company leverages over two decades of imatinib clinical experience, combined with the potential gastrointestinal benefits of IKT-001 (search), to support their belief that IMPROVE-PAH (search) has a high probability of success. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders, with its first reported use in PAH occurring in 2005.
Comprehensive Two-Part Adaptive Trial Design
The global IMPROVE-PAH (search) trial employs a sophisticated two-part adaptive Phase 3 design across approximately 180 sites worldwide. Part A constitutes a double-blind, placebo-controlled study in approximately 140 patients, with a primary endpoint measuring change in Pulmonary Vascular Resistance (PVR) at Week 24.
Part B seamlessly transitions following enrollment completion of Part A, adopting an identical format but shifting the primary endpoint to change in 6-minute walk distance (6MWD) at Week 24 in approximately 346 patients. This design permits uninterrupted enrollment between study parts and includes provisions for sample size re-estimation for Part B based on Part A findings.
The study incorporates a 12-week dose-titration phase designed to optimize patient dosing by achieving the highest tolerable dose of IKT-001 (search). This adaptive approach, confirmed through written FDA responses, represents a strategic refinement of the pivotal Phase 3 design.
Clinical Expert Perspectives on Treatment Need
Dr. Harrison Farber, Co-director of Pulmonary Hypertension Center and Director of the Pulmonary Embolism Response Team (PERT) at Tufts Medical Center, highlighted the clinical rationale for the study. "The Phase 3 IMPRES study demonstrated that imatinib may improve key parameters associated with PAH (search), including exercise capacity and hemodynamics," Farber noted. "Now, the Phase 3 IMPROVE-PAH study will help evaluate both hemodynamic and functional improvements, as well as key measures of disease progression, such as time to clinical worsening."
Farber emphasized the ongoing clinical need, stating, "Despite the availability of multiple therapies, many patients with PAH (search) continue to experience disease progression, so I am always excited about the potential for a novel antiproliferative agent for the treatment of PAH."
Dr. J. Wesley McConnell, Director of Norton Pulmonary Specialists Pulmonary Hypertension Center in Louisville, Kentucky, reinforced this perspective: "For patients living with PAH (search) disease progression remains a daily reality even with the therapies we have available today. The IMPROVE-PAH trial represents a meaningful step forward because the trial is designed to capture the outcomes that matter most to patients and clinicians alike."
Targeting Aberrant Signaling Pathways
Inhibikase focuses on developing therapeutics to modify the course of cardiopulmonary diseases, specifically targeting aberrant signaling through type III receptor tyrosine kinases (search). These include platelet-derived growth factor receptors and a stem cell factor receptor known as "c-Kit (search)," which have been implicated in PAH (search) pathophysiology.
PAH (search) represents a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. The condition affects approximately 50,000 Americans and carries an orphan indication designation, highlighting the significant unmet medical need in this patient population.
Strategic Regulatory Positioning
The IMPROVE-PAH (search) study design reflects strategic regulatory planning, with the adaptive approach and comprehensive endpoint evaluation positioned to support potential regulatory submissions. The company's emphasis on a single pivotal global study represents an efficient pathway toward potential market authorization, leveraging the established safety profile of imatinib while addressing its tolerability limitations through the prodrug formulation.